Bio-Thera Announces BLA Acceptance of Humira’s Biosimilar (BAT1406) by China National Drug Administration (CNDA)

 Bio-Thera Announces BLA Acceptance of Humira’s Biosimilar (BAT1406) by China National Drug Administration (CNDA)

Bio-Thera Announces BLA Acceptance of Humira’s Biosimilar (BAT1406) by China National Drug Administration (CNDA)

Shots:
  •  This BLA is for the treatment of RA, PsA, AS, CD, UC, chronic psoriasis, HS, and JIA
  •   The clinical study included (PK/PD) and Ph III trials in ankylosing spondylitis showing its safety, efficacy and quality
  •  Bio-Thera is developing 7 biosimilars including BAT1406, with Avastin biosimilar currently being assessed in a global Ph III trial

Click here to read full press release/ article | Ref: Businesswire | Image:  LinkedIn

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post